Bayer said Xarelto had “comparable” safety and rates of bleeding versus the standard.
big question is bleeding rates. Were bleeding rates better for Xarelto and how do they compare to rates found in dabigatran RELY study. Guess we'll know by Nov. the 15th.
Market Data 
Markets 
AI
